{
    "root": "312e24b0-f87e-1a24-e063-6294a90a6e7b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valproic Acid",
    "value": "20250325",
    "ingredients": [
        {
            "name": "SORBITOL SOLUTION",
            "code": "8KW3E207O2"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI"
        }
    ],
    "indications": "Valproic acid oral solution is indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications": "Valproic acid oral solution is intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions": "Valproic Acid Oral Solution USP is a clear, red, sour cherry flavored oral solution containing the equivalent of 250 mg valproic acid per 5 mL as the sodium salt and is available as follows:\n                  \n                  NDC: 70518-4298-00\n                  NDC: 70518-4298-01\n                  NDC: 70518-4298-02\n                  NDC: 70518-4298-03\n                  NDC: 70518-4298-04\n                  NDC: 70518-4298-05\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 20 mL in 1 CUP\n                  PACKAGING: 10 in 1 BOX\n                  PACKAGING: 10 mL in 1 CUP\n                  PACKAGING: 10 in 1 BOX \n                  PACKAGING: 5 mL in 1 CUP \n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (\n   \n    5.12)]\n  \n   .\n \n  \n                     Valproic acid is contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (\n   \n    5.6)]\n  \n   .\n \n  \n                     For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\n  \n   [see Warnings and Precautions (\n   \n    5.2,\n   \n    5.3,\n   \n    5.4) and Use in Specific Populations (\n   \n    8.1)]\n  \n   ."
}